Correction: Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis
Jiao Zhang, Jia-xing Guo, Ping Li, Xiao-ye Jin, Yan Wang, Lu-jun Zhao
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLung Cancer Research Studies · Peptidase Inhibition and Analysis · Neuroendocrine Tumor Research Advances
In the Abstract, In the Results section of the Abstract: Line 4: The values “4.14 vs. 2.84” are incorrect. Line 5: The values “4.21 vs. 2.87” are incorrect. This has been corrected to read:
Line 4: The original data has been changed to “4.13 vs. 2.70”. Line 5: The original data has been changed to “4.14 vs. 2.84”.
The original version of this article has been updated.